Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 41,791 |
|
|||||
| News | - | ||||||
| Day High | 3.72 | Low High |
|||||
| Day Low | 3.52 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 3.14% | 3.61 | 10:20:28 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.56 | 3.52 | 3.72 | 3.50 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 277 | 41,791 | $ 3.63 | $ 151,783 | - | 1.28 - 4.2684 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:20:28 | 100 | $ 3.61 | USD |
Galectin Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 222.04M | 61.85M | - | 0 | -44.81M | -0.72 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galectin Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.34 | 3.72 | 2.88 | 3.30 | 224,287 | 0.27 | 8.08% |
| 1 Month | 2.39 | 4.2684 | 2.26 | 3.56 | 322,270 | 1.22 | 51.05% |
| 3 Months | 1.74 | 4.2684 | 1.59 | 3.05 | 159,654 | 1.87 | 107.47% |
| 6 Months | 2.07 | 4.2684 | 1.555 | 2.66 | 107,750 | 1.54 | 74.40% |
| 1 Year | 1.76 | 4.2684 | 1.28 | 2.33 | 81,553 | 1.85 | 105.11% |
| 3 Years | 4.00 | 5.70 | 1.02 | 3.23 | 331,826 | -0.39 | -9.75% |
| 5 Years | 4.75 | 5.70 | 1.02 | 3.03 | 399,415 | -1.14 | -24.00% |
Galectin Therapeutics Description
| Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |
